"The Pitfalls of 'Lose Weight with a Jab'—The Dangers of Misusing Diabetes Medication Mounjaro as a 'Diet Injection' and the Reality of Reselling in China"

1. Introduction: The Background of the Spread of the "Inject and Lose Weight" Magic Phrase

"Inject and lose weight"—this provocative phrase has caused Mounjaro to go viral on social media. Originally a diabetes medication, this injectable drug is being spread for beauty and weight loss purposes, with users sharing experiences of "astonishing weight loss" alongside suffering from side effects. Television reports have also covered the spread of off-label prescriptions and resales, as well as high-priced sales in China.FNN Prime OnlineFNN Prime OnlineChiba TV

Behind this movement are the psychology of seeking immediate effects, the amplification of "success stories" by social media algorithms, and gaps in medical access, price differences, and regulations. The core issue is the tendency to start self-injecting without understanding the true nature and risks of the drug, based solely on others' success stories.LillyAP News

2. What is Mounjaro?—Mechanism of Action, Approved Uses, and Dosage

Mounjaro is a once-weekly injectable drug developed by Eli Lilly, with tirzepatide as its active ingredient. It was approved in the U.S. in 2022 as a treatment for type 2 diabetes. It works on two gut hormone receptors, GLP-1 and GIP, promoting insulin secretion, suppressing appetite, and delaying gastric emptying.FDA Access DataFDA Access Data

The U.S. FDA's package insert includes a boxed warning about the risk of thyroid C-cell tumors (observed in rats), and cautions against severe gastrointestinal symptoms, dehydration-related kidney function deterioration, and pancreatitis as serious side effects.FDA Access DataFDA Access Data

3. Current Situation in Japan: "Slimming Injections" in Private Clinics and Shortages and High Prices

In Japan, even drugs approved for diabetes treatment are not approved for weight loss purposes. Therefore, more beauty clinics and private clinics are offering them as part of "medical diet plans." Reports indicate that expensive courses, such as 88,000 yen for three months, are being offered, with individuals self-injecting once a week.FNN Prime OnlineFNN Prime Online

Medical societies and companies are also issuing warnings. The Japan Diabetes Society published a statement on off-label use of GLP-1/GIP drugs in November 2023, and pharmaceutical companies are emphasizing proper use.Novo NordiskPMDA

4. Doctors Warn of "Life-Threatening Possibilities"—What Side Effects Are Frightening?

The strong warning from doctors in TV interviews about "life-threatening possibilities" is based on the following risks.FNN Prime OnlineFNN Prime Online

• Acute Pancreatitis: Numerous reports with GLP-1 drugs. Studies show increased pancreatitis risk compared to other drugs (HR 9.09).PMCPMC

• Intestinal Obstruction/Gastroparesis (Delayed Gastric Emptying): Severe gastrointestinal disorders can occur due to suppressed gastrointestinal motility.PMCPMC

• Dehydration/Acute Kidney Injury: Severe vomiting or diarrhea can worsen kidney function, as warned in package inserts.FDA Access Data

• Thyroid C-cell Tumors (Rats)/Unknown Risk in Humans: Subject to boxed warning.FDA Access Data

• Hypoglycemia: When the effect as a diabetes treatment drug works excessively.FDA Access Data
  
  
  

Such side effects can be detected and managed early only under "medical supervision" and with "appropriate testing and monitoring." Self-injection in private clinics carries a high risk of missing symptoms and worsening conditions.Novo NordiskPMDA

5. High-Priced Resales in China—The Structure of Cross-Border SNS Markets

FNN's investigation found numerous resale posts for Mounjaro on social media, reporting that it was being sold at high prices in China.FNN Prime Online Behind this are

• Price and Availability Differences (sourcing cheaper from Japan or the U.S. and selling at a high price)
  
  

• Infiltration of Counterfeit and Substandard Products Disguised as Genuine
  
  

• Anonymous Transactions on SNS and Cross-Border EC Platforms (WeChat, Xiaohongshu, etc.)
  
  
  Such drugs obtained through non-official routes carry high risks of ingredient falsification and unsanitary manufacturing environments, as warned by the FDA, WHO, and manufacturers.LillyAP NewsU.S. Food and Drug Administration
  
  

6. The Context of the Global "Weight Loss Drug" Boom: Comparison with Ozempic/Wegovy/Zepbound

Mounjaro, the weight-loss drug Zepbound with the same active ingredient, and Novo Nordisk's Ozempic (diabetes) and Wegovy (obesity) are part of a global boom in GLP-1 drugs. In the U.S., compounding pharmacies have started making "copy formulations" amid shortages, leading to market chaos, according to reports.The GuardianThe Wall Street Journal

In Japan, Wegovy has just been approved, and supply is limited, leading to potentially high demand for "alternative routes." As a result, reliance on off-label prescriptions, personal imports, and resales is likely to increase.Novo NordiskPMDA

7. Law and Ethics: Proper Use, Pharmaceutical Affairs Law, Medical Practitioners Law, and the Gray Zone of Personal Imports

• Off-Label Prescriptions: Legal at the discretion of the physician, but with heavy obligations for explanation and responsibility. Problems arise without sufficient informed consent.Novo NordiskPMDA
  
  

• Pharmaceutical Affairs Law: Prohibits unauthorized sales and advertising; resales may